Beacon Investment Advisory Services Inc. Has $17.68 Million Stake in Danaher Corporation $DHR

Beacon Investment Advisory Services Inc. cut its holdings in Danaher Corporation (NYSE:DHR) by 8.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 89,179 shares of the conglomerate’s stock after selling 8,224 shares during the period. Beacon Investment Advisory Services Inc.’s holdings in Danaher were worth $17,681,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. White Pine Capital LLC boosted its stake in Danaher by 1.4% during the second quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock worth $690,000 after acquiring an additional 49 shares in the last quarter. Boyd Watterson Asset Management LLC OH increased its stake in Danaher by 2.1% in the second quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock valued at $499,000 after purchasing an additional 51 shares in the last quarter. Worth Financial Advisory Group LLC raised its holdings in shares of Danaher by 4.6% during the second quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock valued at $236,000 after purchasing an additional 53 shares during the period. Bruce G. Allen Investments LLC grew its stake in shares of Danaher by 13.1% in the 2nd quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock valued at $92,000 after buying an additional 54 shares during the period. Finally, Texas Bank & Trust Co increased its position in Danaher by 1.6% in the 2nd quarter. Texas Bank & Trust Co now owns 3,567 shares of the conglomerate’s stock valued at $705,000 after buying an additional 55 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 21,776 shares of Danaher stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the transaction, the senior vice president directly owned 14,553 shares in the company, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Teri List sold 3,298 shares of the business’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the sale, the director owned 20,762 shares in the company, valued at approximately $4,702,593. The trade was a 13.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,248 shares of company stock valued at $6,609,663 over the last three months. 11.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

DHR has been the subject of several research reports. Barclays lifted their price target on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a report on Tuesday, September 2nd. Wells Fargo & Company boosted their target price on shares of Danaher from $230.00 to $240.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. Cowen restated a “buy” rating on shares of Danaher in a report on Wednesday, October 22nd. Finally, Robert W. Baird set a $247.00 price target on Danaher in a research note on Wednesday, October 22nd. Twenty-one equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $248.25.

Danaher Stock Down 0.4%

DHR opened at $230.52 on Friday. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $258.23. The company’s 50-day moving average price is $222.66 and its two-hundred day moving average price is $208.15. The stock has a market cap of $162.83 billion, a price-to-earnings ratio of 47.53, a PEG ratio of 4.48 and a beta of 0.89. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. During the same quarter in the previous year, the firm posted $1.71 EPS. Danaher’s revenue was up 4.4% on a year-over-year basis. As a group, equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, December 26th. Danaher’s payout ratio is currently 26.39%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.